Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]
Conditions
Interventions
Intervention1: Oral eltrombopag: Oral eltrombopag, administered orally, according to the age group.
•2-6 years: 25 mg/ day (1 tablet of 25 mg)
•7-12 years: 50 mg/ day (2 tablets of 25 mg)
•13-18 years
Sponsors
AIIMS, Bhubaneswar
Eligibility
Inclusion criteria
Inclusion criteria: SGOT/SGPT Normal cardiac and renal functions Written informed consent
Exclusion criteria
Exclusion criteria: a. Relapsed acute lymphoblastic leukemia and lymphoma b. Mixed phenotype acute leukemia c. Presence of hemodynamic compromise requiring vasoactive support at enrolment d. Presence of respiratory failure at enrolment e. Received therapy prior to presentation at treating centre (Excluding steroids up to 7 days) f. Hepatitis B/ C infection g. Known thrombophilia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Episodes and site of bleeding 2. Number and volume of platelet transfusionsTimepoint: End of induction chemotherapy (5 weeks) and end of consolidation chemotherapy (9 weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects associated with eltrombopag in patients with acute leukemiaTimepoint: End of induction chemotherapy (5 weeks) & end of consolidation chemotherapy (9 weeks);Complete remission rates & MRD negativity at end of inductionTimepoint: End of induction chemotherapy (5 weeks) | — |
Countries
India
Contacts
Public ContactDEBASISH SAHOO
AIIMS, Bhubaneswar
Outcome results
None listed